Glenmark confirms Vimpat challenge

16-07-2013

Pharmaceutical company Glenmark Generics has confirmed that it has filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of epilepsy drug Vimpat.


Glenmark, UCB, Vimpat, ANDA, patent infringement

LSIPR